A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Trial Profile

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DOL-ART
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 27 Oct 2017 Results of 2nd interim analysis (data cut 27 months after last patient in) assessing safety and efficacy presented at the 16th European AIDS Conference
    • 23 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top